Note: All samples should be forwarded to LabPlus at room temperature within 24hours.
4 mL CPD Blood (Preferred) 4 mL CPD Bone Marrow (Preferred) 4 mL EDTA Blood 4 mL EDTA Bone Marrow Turnaround Time: Within 2 weeks, 4 days Diagnostic Use and Interpretation
This test looks for the FLT3 Internal Tandem Duplication (ITD) and D835 acquired mutations commonly seen in AML patients.
FLT3 Allelic Ratio Analysis
NPM1 Mutation Analysis
To contact the Molecular Haematology team please call:
Auckland City Hospital (09) 307 4949 Lablink ext 22000 Prof. Peter Browett (Haematologist) ext 9090-86281 Nikhil Ghallayan (Section Leader) ext 22006 Molecular Haematology Lab ext 22005
For more inforamtion about the Molecular Haematology service at LabPLUS:
Molecular Haematology information page
FLT3 is a receptor tyrosine kinase which is preferentially expressed on the surface of acute myeloid leukaemia (AML) and B cell-lineage acute lymphoblastic leukaemia (ALL) cells. Mutations in the FLT3 gene are the most frequent genetic alterations in AML patients. The majority of FLT3 mutations in AML are either internal tandem duplications (ITD) (15-35%) or a missense mutation of D835 within the activation loop (5-10%). Both of these mutations can be identified by PCR using genomic DNA. The ITD mutations can be identified directly on an agarose gel and the D835 mutations by Eco RV digestion of a PCR product.
Kiyoi H and Naoe T. Methods in Mol Med (2006), 125, 189-197.
Kiyoi H and Naoe T. Int J Hematol (2006), 83, 301-308.